Merck KGaA Add to portfolio

DAXX:MRK, Nov 25, 02:43 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Friday, November 13


News

HUGO BOSS to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 19 November 2020

MRK DBK

METZINGEN, Germany, Nov. 13, 2020 /PRNewswire/ -- HUGO BOSS (OTCQX: BOSSY) based in Metzingen, and focused on developing and selling high-quality fashion as well as accessories in the womenswear and menswear segments under the BOSS and HUGO brands, today announced that Frank Böhme, Senior Investor Relations Manager will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on November 19. This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the organization's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. The collections of its two brands BOSS and HUGO seek to offer customers a comprehensive selection of modern tailoring, elegant evening wear, casualwear, shoes and accessories.

Read Full Details

Topics:
  • Business
  • Financial
  • Science

Thursday, November 12


News

Top Stock Reports for Coca-Cola, Merck & Honeywell

MRK KO +2 more MRK KO GE HON

Today's Research Daily features new research reports on 16 major stocks, including Coca-Cola Company (KO), Merck (MRK) and Honeywell International (HON). The Zacks analyst believes that it is poised to gain from the streamlining of portfolio and accelerating investments to expand digital presence due to a shift in consumer preference. However, continued pressures in the away-from-home channel, which account for nearly half of its revenues, hurt revenue growth. Moreover, revenues surpassed the Zacks Consensus Estimate. Although the earnings and sales declined on a year-over-year basis, the company’s third-quarter revenues and volume reflected improved trends from the second quarter. The Zacks analyst believes that strength in defense and space businesses as well as solid demand for warehouse automation products are likely to boost Honeywell’s revenues in the quarters ahead. Solid demand for personal protective equipment, along with a strong backlog conversion rate, will act as tailwinds.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, November 11


News

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study - November 11, 2020

MRK

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study. Merck (MRK Quick QuoteMRK - Free Report) and partner Eisai (ESALY Quick QuoteESALY - Free Report) announced positive top-line data from a pivotal phase III study evaluating a combination of Merck’s anti-PD-1 therapy, Keytruda,plus Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima for the first-line treatment of patients with advanced renal cell carcinoma (RCC),a kind of kidney cancer. The results from the KEYNOTE-581/CLEAR (Study 307) study showedthat Keytruda plus Lenvima demonstrated statistically significant improvement in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) versus Pfizer’s (PFE Quick QuotePFE - Free Report) RCC drug, Sutent (sunitinib), in the intention-to-treat (ITT) study population. The companies are also continuing to study the Keytruda plus Lenvima combination through the LEAP (LEnvatinib and Pembrolizumab) clinical program across 19 studies in 13 different tumor types.

Read Full Details

Topics:
  • Business
  • Health

Wednesday, November 04


News

UnitedHealth, Merck share gains contribute to Dow's nearly 750-point surge

MRK UNH

Buoyed by strong returns for shares of UnitedHealth and Merck, the Dow Jones Industrial Average is soaring Wednesday afternoon. UnitedHealth's shares are up $37.07 (11.5%) while those of Merck have risen $5.63 (7.3%). A $1 move in any one of the 30 components of the Dow equates to a 6.58-point swing.... Shares of UnitedHealth UNH and Merck MRK contributed significantly to the blue-chip gauge's intraday rally, as the Dow DJIA is trading 747 points higher (2.7%).

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, October 27


News

Justice barrett, earnings (HSBC, BP,Pfizer, merck), CNY, oil edges higher, gold a touch softer

MRK PFE +1 more MRK PFE BP

Republicans are hoping for a strong Election Day turnout, but it seems President Trump has not been able to gain much momentum following the last debate. BP's refining margins are under pressure and production is set to decline, however the oil giant avoided major write-offs and did not have to take on more debt. Oil's short-term bearish drivers remain the restart of all of Libya's major oil fields, rising expectations European governments can't avoid a return to lockdowns, concerns that treatments and vaccines might take longer for approval, and broader market weakness on failed attempts to get a stimulus done this side of the election. Energy markets might be looking ahead to the presidential election which could deliver a ‘blue wave' that would deliver a mask mandate and further aid in testing and fighting the coronavirus, ultimately easing extended lockdown fears and providing optimism for the crude demand outlook.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance

MRK

The Pharmaceutical segment generated revenues of $11.32 billion, up 2% (up 2% excluding Fx impact) year over year driven by strong demands for cancer drugs and certain hospital acute care products. However, the negative impact of the COVID-19 pandemic on prescription trends of some drugs and generic competition for legacy drugs partially offset the growth. In vaccines, Gardasil/Gardasil 9 sales declined 10% year over year to $1.19 billion as COVID-19 hurt sales of the vaccine due to lower back-to-school demand in the United States, partially offset by higher volumes in Europe and China.In addition, the phasing of the recovery of GARDASIL 9 demand is slower than originally anticipated, particularly in the United States. Merck’s third-quarter results were promising as the company beat estimates for both earnings and sales. Although COVID-19 related business disruptions hurt Merck’s third-quarter revenues by $475 million, it was an improvement compared to second-quarter’s impact of $1.6 billion. The company also raised its earnings guidance for the year, which pushed its shares up almost 1.9% in pre-market trading. However, the sales guidance was slightly lowered as the company expects some residual negative impacts from COVID-19 in the fourth quarter.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Merck (MRK) earnings Q3 2020

MRK

Merck raises annual profit outlook as Keytruda drives profit beat. The upbeat results showed Merck was on a recovery path after its revenue took a hit at the height of the pandemic, nudging the company's shares about 2% higher in premarket trading. Sales of Keytruda, which is an approved treatment for cancers including non-small-cell lung cancer, rose 21% to $3.7 billion, above analysts estimates of $3.66 billion, according to six analysts polled by Refinitiv. Merck said it now expects full-year adjusted profit of between $5.91 and $6.01 per share, compared with its prior forecast of between $5.63 to $5.78 per share. For 2020, Merck now expects an unfavorable impact to revenue of about $2.35 billion due to the pandemic, up from $1.95 billion it had initially estimated.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Wednesday, October 14


News

Merck Issues 2019/2020 Corporate Responsibility Report

MRK

"At Merck, we embrace our responsibility to be a force for good in the world – not only through our medicines and vaccines but also through our broader actions to address systemic inequities and to create an environment where all people are valued and respected." The report reflects the company’s belief that serving social good and achieving business success are deeply interdependent. For the second year, Merck has published a separate environmental, social and governance (ESG) report that details progress toward the Global Reporting Initiative and the Sustainability Accounting Standards Board standards. The company also has incorporated reporting against the new Culture of Health for Business (COH4B) framework focused on managing impact on health of employees, families and communities. Recognizing changing global access needs, Merck conducted a strategic reevaluation of its Access to Health Guiding Principles.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Friday, October 09


News

Precigen Announces Merck KGaA, Darmstadt, Germany Increases Ownership Position Through Exercise of Convertible Note

MRK

GERMANTOWN, Md., Oct. 9, 2020 /PRNewswire/ --Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading S.A., has elected to voluntarily convert a convertible note with an outstanding principal balance of $25 million to increase its stake in Precigen from approximately 11.6% to 14.8% of outstanding shares, remaining as Precigen's second largest shareholder. As previously announced in December 2018, Merck KGaA, Darmstadt, Germany, reassigned to Precigen exclusive chimeric antigen receptor T-cell (CAR-T) development rights that were part of an earlier transaction between the companies. The relationship between Precigen and Merck KGaA, Darmstadt, Germany is longstanding, dating back to 2015 when the two companies signed an agreement to develop and commercialize CAR-T cancer therapies utilizing Precigen's proprietary Sleeping Beauty non-viral gene integration technology. This technology has evolved into Precigen's UltraCAR-T®next generation CAR-T therapies, which have demonstrated superior efficacy in preclinical studies and combine rapid manufacturing to improve time to treatment. Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Science

Thursday, October 08


News

Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection

MRK

Treatment With Islatravir and Doravirine Maintained Viral Suppression and No Viral Resistance was Identified. DELSTRIGO (doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) is indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. eGFR <60 mL/min/1.73 m2 occurred in 4% (4/90) of islatravir-treated participants and were transient in three (the fourth had eGFR <60 mL/min/1.73 m2 from baseline through Week 96). Immune reconstitution syndrome can occur, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment. Because DELSTRIGO is a complete regimen, co-administration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.

Read Full Details

Topics:
  • Business
  • Health
  • Technology